Background: Despite the worldwide progress in cancer diagnostics, more sensitive diagnostic biomarkers are needed. The methylome has been extensively investigated in the last decades, but a low-cost, bisulfite-free detection method for multiplex analysis is still lacking. Methods: We developed a methylation detection technique called IMPRESS, which combines methylation-sensitive restriction enzymes and single-molecule Molecular Inversion Probes. We used this technique for the development of a multi-cancer detection assay for eight of the most lethal cancer types worldwide. We selected 1791 CpG sites that can distinguish tumor from normal tissue based on DNA methylation. These sites were analysed with IMPRESS in 35 blood, 111 tumor and 114 normal samples. Finally, a classifier model was built. Results: We present the successful development of IMPRESS and validated it with ddPCR. The final classifier model discriminating tumor from normal samples was built with 358 CpG target sites and reached a sensitivity of 0.95 and a specificity of 0.91. Moreover, we provide data that highlight IMPRESS’s potential for liquid biopsies. Conclusions: We successfully created an innovative DNA methylation detection technique. By combining this method with a new multi-cancer biomarker panel, we developed a sensitive and specific multi-cancer assay, with potential use in liquid biopsies.
Pleural mesothelioma (PM) is a rare and aggressive cancer that often requires multiple diagnostic procedures before a definitive diagnosis can be made. To improve diagnostic accuracy, we developed a DNA methylation‐based biomarker assay capable of distinguishing PM from healthy pleura and other pleural pathologies. Using Infinium EPIC array data, we identified 744 hypermethylated CpG sites in PM as candidate biomarkers. These were validated in silico using external datasets, yielding a high mean AUC of 0.935. Clinical validation was performed using IMPRESS, a novel bisulfite‐free methylation detection technique that enables simultaneous analysis of thousands of CpG sites. A two‐step classifier approach was applied: the first model differentiated tumoral from nontumoral pleura with 89.2% sensitivity and 93.5% specificity, while the second model distinguished PM from pleural metastases with 85.2% sensitivity and 100% specificity. These results demonstrate that our methylation‐based biomarker panel offers a highly accurate and minimally invasive tool for differentiating PM from other pleural conditions, potentially streamlining the diagnostic process and improving clinical decision‐making.
Pleural mesothelioma (PM) is a rare and aggressive cancer primarily caused by asbestos exposure. Its late diagnosis, due to non-specific symptoms and challenges in distinguishing it from other lung diseases, contributes to poor patient outcomes. Recent advancements in DNA methylation analysis offer new opportunities for improving PM diagnostics. This thesis investigates the potential of DNA methylation as a diagnostic tool, presenting novel approaches for early and accurate detection of PM. The first part of the research identifies methylation biomarkers for PM using EPIC methylation arrays on 11 PM samples and 29 healthy pleura samples, supplemented by public datasets of other lung-related diseases. The study reveals 81,968 differentially methylated CpG sites between PM and healthy pleura. Importantly, these methylation profiles enable clear differentiation of PM from other lung cancers, addressing a critical diagnostic challenge. To facilitate cost-effective and scalable methylation analysis, a novel technology, IMPRESS (Improved Methylation Profiling using Restriction Enzymes and smMIP Sequencing), was developed. IMPRESS combines methylation-sensitive restriction enzymes and single-molecule Molecular Inversion Probes to analyze thousands of CpG sites. Validation on a multi-cancer assay targeting 1,791 CpGs across eight cancer types achieved a sensitivity of 95% and specificity of 91%. This technology demonstrated high potential for non-invasive diagnostics using liquid biopsies. In the final part, the identified PM-specific methylation biomarkers were integrated into IMPRESS to develop an assay for distinguishing PM from healthy pleura and other pleural pathologies. A stepwise diagnostic model achieved sensitivities of 88.9% and 80.8% and specificities of 93.3% and 100% for differentiating PM from non-tumoral conditions and pleural metastases, respectively. This thesis highlights the promise of DNA methylation analysis for PM diagnostics. The combination of novel biomarkers and the IMPRESS platform offers a robust, cost-effective, and scalable solution for early cancer detection. These findings provide a foundation for integrating methylation-based assays into clinical practice, potentially improving early diagnosis, treatment, and patient outcomes in PM and other cancers.